Using data from a 2015 study on birth control access by Bixby researchers, the Brookings Institute and Child Trends produced a report estimating the impact and cost savings that would result from every woman having full access to the most effective contraceptive methods.
Nearly half of pregnancies in the U.S. are unintended, and many result from people failing to use contraception correctly or consistently. One way to improve contraceptive use is to help women select contraceptive methods that better accommodate their personal preferences.
In a recent New England Journal of Medicine commentary, a group of experts including the Bixby Center’s Dr. Daniel Grossman called on the FDA to eliminate the FDA's excessive regulation of the medication abortion drug mifepristone.
A group of experts, including Daniel Grossman, MD, director of ANSIRH and Bixby Center member, calls for an end to the FDA's overregulation of Mifeprex (mifepristone), a drug commonly used in medication abortions.